BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
Oct. 4, 2006
View Archived Issues
ProStrakan's Agreement With Novartis Could Reach $140M
LONDON - ProStrakan Group plc sealed a deal with a headline value of $140 million under which Novartis AG will develop antibody treatments for bone-related diseases using a ProStrakan target. (BioWorld International)
Read More
Crucell Pays Acambis $16.5M To Obtain Vivotif's U.S. Rights
Read More
Study: Alzheimer's Protein Has Role In Cell Signalling
Read More
EU Pharmaceutical Forum Calls For Research Support
Read More
RNAi Deal Involves Quark, Pfizer, Atugen, SR Pharma
Read More
Roslin Institute Forms Facility For Producing Stem Cell Lines
Read More
Pharmaxon's Seed Financing For Nervous System Diseases
Read More
Gamida Cell Raises $16M To Broaden Its Programs
Read More
Other News To Note
Read More